Maze Therapeutics (NASDAQ:MAZE) was given a new $55.00 price target on by analysts at Wells Fargo & Company. They now have an "overweight" rating on the stock.
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Maze Therapeutics, Inc. (MAZE) Presents at Jefferies London Healthcare Conference 2025 Prepared Remarks Transcript [Seeking Alpha]
Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.
Maze Therapeutics (NASDAQ:MAZE) was downgraded by analysts at
Wall Stree